

Mark W. Kieran, MD, PhD

Dr. Kieran is currently the VP of Clinical Development at Day One Biopharmaceuticals, a company focused on the development of targeted drugs for children. He received a PhD in Immunology from the University of Alberta, Canada in 1998 and his MD in 1986 from the University of Calgary. After a post-doctoral fellowship in the Department of Molecular Biology at the Pasteur Institute in Paris, France where he cloned the regulatory molecule NF κ B, he completed a pediatric residency at McGill University in Montreal and a pediatric oncology fellowship at Boston Children's Hospital. Dr. Kieran became Director of Pediatric Neuro-Oncology at the Dana-Farber Cancer Institute in 1998 focused on targeted, gene, immune modulatory and antiangiogenic therapies for pediatric brain tumor patients and other rare cardiac and premature aging diseases. Dr Kieran moved to Bristol-Myers Squibb in 2018 where he was the Senior Director of Pediatric Oncology until July 2021.